CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Sold by Loomis Sayles & Co. L P

Loomis Sayles & Co. L P decreased its holdings in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 3.6% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 910,965 shares of the company's stock after selling 34,302 shares during the quarter. Loomis Sayles & Co. L P owned 1.07% of CRISPR Therapeutics worth $35,856,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of CRSP. ARK Investment Management LLC grew its position in CRISPR Therapeutics by 19.7% in the 4th quarter. ARK Investment Management LLC now owns 8,973,064 shares of the company's stock valued at $353,180,000 after acquiring an additional 1,474,439 shares during the last quarter. Baker BROS. Advisors LP grew its holdings in shares of CRISPR Therapeutics by 743.1% in the third quarter. Baker BROS. Advisors LP now owns 843,075 shares of the company's stock worth $39,608,000 after purchasing an additional 743,075 shares during the last quarter. State Street Corp lifted its holdings in CRISPR Therapeutics by 25.0% during the 3rd quarter. State Street Corp now owns 2,992,988 shares of the company's stock valued at $140,611,000 after buying an additional 599,304 shares in the last quarter. Contrarius Group Holdings Ltd purchased a new stake in CRISPR Therapeutics in the 4th quarter valued at about $14,516,000. Finally, Raymond James Financial Inc. bought a new position in CRISPR Therapeutics in the 4th quarter worth about $3,231,000. Institutional investors own 69.20% of the company's stock.

Insiders Place Their Bets

In other news, CEO Samarth Kulkarni sold 18,360 shares of CRISPR Therapeutics stock in a transaction that occurred on Wednesday, February 19th. The stock was sold at an average price of $55.20, for a total value of $1,013,472.00. Following the sale, the chief executive officer now directly owns 171,613 shares of the company's stock, valued at $9,473,037.60. The trade was a 9.66 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, General Counsel James R. Kasinger sold 2,850 shares of the stock in a transaction on Tuesday, March 11th. The shares were sold at an average price of $42.42, for a total value of $120,897.00. Following the completion of the transaction, the general counsel now directly owns 77,530 shares of the company's stock, valued at approximately $3,288,822.60. This represents a 3.55 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 32,381 shares of company stock worth $1,608,243. 4.10% of the stock is owned by corporate insiders.

Remove Ads

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the stock. Truist Financial lifted their price target on shares of CRISPR Therapeutics from $100.00 to $120.00 and gave the company a "buy" rating in a research note on Wednesday, February 12th. HC Wainwright reiterated a "buy" rating and issued a $65.00 target price on shares of CRISPR Therapeutics in a report on Thursday, February 13th. Royal Bank of Canada decreased their price objective on CRISPR Therapeutics from $53.00 to $48.00 and set a "sector perform" rating for the company in a report on Wednesday, February 12th. Needham & Company LLC reissued a "buy" rating and set a $84.00 target price on shares of CRISPR Therapeutics in a research report on Wednesday, February 12th. Finally, Cantor Fitzgerald reaffirmed a "neutral" rating on shares of CRISPR Therapeutics in a research report on Wednesday, February 19th. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating and eleven have given a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Hold" and an average price target of $73.11.

CRISPR Therapeutics Trading Up 2.4 %

NASDAQ CRSP traded up $0.81 on Tuesday, hitting $34.84. 668,767 shares of the company's stock traded hands, compared to its average volume of 1,558,009. The firm has a market capitalization of $2.99 billion, a PE ratio of -7.93 and a beta of 1.77. CRISPR Therapeutics AG has a 1-year low of $32.96 and a 1-year high of $68.39. The firm's 50-day moving average price is $42.97 and its two-hundred day moving average price is $45.09.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last issued its quarterly earnings data on Tuesday, February 11th. The company reported ($0.44) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.15) by $0.71. CRISPR Therapeutics had a negative return on equity of 18.46% and a negative net margin of 981.54%. On average, research analysts anticipate that CRISPR Therapeutics AG will post -5.16 earnings per share for the current fiscal year.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.